ga 68-edotreotide
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2013 (NCT01869725)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Somatostatin receptorRadiopharmaceutical
Somatostatin receptor radiopharmaceutical
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ga 68-edotreotide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06717113 | Early Phase 1 (Phase 1) | Dec 15, 2024 | Peking University |
| NCT02194452 | N/A | Sep 1, 2013 | National Cancer Institute (NCI), Ride for Kids, University of Iowa |
| NCT01869725 | N/A | Apr 1, 2013 | National Cancer Institute (NCI), University of Iowa |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 2013 |
| University of Iowa | Academic/Hospital | 2 | 2 | 1 | 2013 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Ride for Kids | Academic/Hospital | 1 | 0 | 1 | 2013 |
4 organizations
Page 1 / 1